Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

INSIDE INFORMATION ANNOUNCEMENT

LICENSE AGREEMENT WITH EISAI IN RESPECT OF HANSIZHUANG

A. INTRODUCTION

This announcement is made by Shanghai Henlius Biotech, Inc. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company is pleased to announce that on 5 February 2026, the Company entered into a license agreement (the "**License Agreement**") with Eisai Co., Ltd. ("**Eisai**"), pursuant to which, the Company granted Eisai a license to develop, manufacture and commercialise HANSIZHUANG (serplulimab injection) (the "**Licensed Product**") in the Field (as defined below) in Japan (the "**Territory**").

B. PRINCIPAL TERMS OF THE LICENSE AGREEMENT

License

The Company will grant to Eisai:

(a) an exclusive license to commercialise the Licensed Product in the Field in the Territory; and

(b) a co-exclusive license (i.e. the Company also have the right to develop and manufacture) to develop and manufacture the Licensed Product in the Field in the Territory solely for the purposes of paragraph (a) above.

Field

The use of the Licensed Product in the treatment of oncology indications.

Payments and Royalties Eisai shall pay the Company:

(a) an upfront fee of US$75 million, upon the execution of the License Agreement;

(b) regulatory milestone payments of up to US$80.01 million in aggregate based on achievements of each regulatory milestone of the Licensed Product in the Territory;

(c) commercial sales milestone payments of up to US$233.33 million in aggregate based on each achievement of level of annual net sales of Licensed Product in the Territory; and

(d) royalties of double-digit percentages of the annual net sales of Licensed Product in the Territory.

Term The License Agreement is effective from the date of its execution, unless earlier terminated in accordance with the terms therein, remain in effect until 5 years after the expiration of the Royalty Term. Royalty Term shall be from the first commercial sale of the Licensed Product in the Territory to the latest of: (a) 10 years from the first commercial sale of the Licensed Product in the Territory, (b) the expiration of regulatory marketing exclusivity for the Licensed Product in the Territory; or (c) the expiration, invalidation or abandonment of the last valid claim of patent that covers the Licensed Product compound in the Territory.

C. INFORMATION ABOUT THE LICENSED PRODUCT

HANSIZHUANG (serplulimab injection) is an innovative anti-PD-1 monoclonal antibody independently developed by the Company, which was approved for marketing in Chinese Mainland (excluding Hong Kong, Macau and Taiwan regions of China, same as below) for indications including the combination with chemotherapy for the first-line treatment of squamous non-small cell lung cancer (sq-NSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsq-NSCLC). Meanwhile, HANSIZHUANG was approved for marketing in the European Union, the United Kingdom, Indonesia, Cambodia, Thailand, Malaysia, Singapore, India and other countries/regions respectively, and has been granted orphan-drug designations by drug regulatory authorities in the United States, the European Union, Switzerland, the Republic of Korea and other countries/regions, respectively. In addition, the Company is in the process of advancing a number of clinical studies of HANSIZHUANG and related combination therapies globally, covering a wide range of indications such as lung cancer, esophageal carcinoma, head and neck squamous cell carcinoma, colorectal cancer and gastric cancer. In December 2025, the drug registration application of HANSIZHUANG in combination with chemotherapy for neo-/adjuvant treatment for gastric cancer has been accepted by the National Medical Products Administration (NMPA), and has been granted the procedure for priority review.

The sales promotion of HANSIZHUANG in Chinese Mainland is conducted by the Company's inhouse commercialisation team. As of the date of this announcement, the Company has entered into business partnerships with multiple internationally renowned partners for commercialisation of HANSIZHUANG in over 100 countries and regions worldwide.

According to the latest information provided by IQVIA MIDAS™ (IQVIA is a global provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), the worldwide sales of monoclonal antibody drugs targeting PD-1 amounted to approximately US$45.7 billion in 2024.

D. REASONS AND BENEFITS OF THE LICENSE AGREEMENT

The collaboration with Eisai on the commercialisation of the Licensed Product in the Territory will help further promote the overseas market expansion of the Licensed Product, strengthen the accessibility and acceptance of the Company's products in global markets and contribute to the continuous increase in the Company's revenue.

E. INFORMATION ABOUT EISAI

Eisai is a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (stock code: 4523). Eisai mainly focuses on the research and development, manufacture as well as sale of pharmaceuticals in the fields of neuroscience and oncology.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 5 February 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.